Literature DB >> 27423416

Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.

Ik Sung Choi1, Yu Ji Lee2, Yu Mi Wi3, Byung Soo Kwan1, Kae Hwa Jung1, Woong Pyo Hong1, June Myong Kim4.   

Abstract

The ratio of the area under the free (unbound) concentration-time curve to minimum inhibitory concentration (fAUC/MIC) was proposed to be the pharmacokinetic/pharmacodynamic index most strongly linked to the antibacterial effect of colistin against Acinetobacter baumannii. A retrospective study of patients who received colistin to treat pneumonia caused by extensively drug-resistant (XDR) A. baumannii over a 4-year period was performed to assess the impact of the colistin MIC on mortality. A total of 227 patients were included in the analysis. The 7-day and 14-day mortality rates of patients with XDR A. baumannii pneumonia receiving colistin therapy were 15.0% and 23.8%, respectively. In the multivariate analysis, Acute Physiology and Chronic Health Evaluation (APACHE) II score, days from index culture to first dose of colistin, underlying tumour and septic shock at presentation were independent predictors of mortality in patients with XDR A. baumannii pneumonia receiving colistin therapy. In the univariate analysis, the colistin dose based on ideal body weight (IBW) correlated with patient outcome. Therefore, the use of IBW appeared to be more appropriate to calculate the colistin dosage. In addition, these results highlight the clinical significance of colistin MIC in patients with XDR A. baumannii pneumonia receiving colistin therapy. Although MICs were in the 'susceptible' range, patients infected with isolates with high colistin MICs showed a poorer clinical response rate than patients infected with isolates with low colistin MICs. Further clinical studies are needed to evaluate the roles of colistin MIC for predicting mortality in XDR A. baumannii pneumonia with a high colistin MIC.
Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Colistin; Pneumonia; Predictor

Mesh:

Substances:

Year:  2016        PMID: 27423416     DOI: 10.1016/j.ijantimicag.2016.05.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

Review 1.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.

Authors:  Yu Mi Wi; Kerryl E Greenwood-Quaintance; Audrey N Schuetz; Kwan Soo Ko; Kyong Ran Peck; Jae-Hoon Song; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia.

Authors:  Hyo-Ju Son; Eun Been Cho; Moonsuk Bae; Seung Cheol Lee; Heungsup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Open Forum Infect Dis       Date:  2020-08-24       Impact factor: 3.835

4.  Differences in Colistin Administration and Bacterial and Treatment Outcomes in Critically Ill Patients.

Authors:  Sunmi Jung; Eun Kyoung Chung; Min Sun Jun; Eun Sun Son; Sandy Jeong Rhie
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

5.  Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli.

Authors:  Kamonchanok Jitaree; Korbtham Sathirakul; Jantana Houngsaitong; Orarik Asuphon; Weerayuth Saelim; Visanu Thamlikitkul; Preecha Montakantikul
Journal:  Antibiotics (Basel)       Date:  2019-08-22

6.  Clinical Features and Outcomes of Monobacterial and Polybacterial Episodes of Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii.

Authors:  Dalia Adukauskiene; Ausra Ciginskiene; Agne Adukauskaite; Despoina Koulenti; Jordi Rello
Journal:  Antibiotics (Basel)       Date:  2022-07-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.